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Abstract
Background: One of the primary objectives in cancer research is to identify causal genomic alterations, such as
somatic copy number variation (CNV) and somatic mutations, during tumor development. Many valuable studies
lack genomic data to detect CNV; therefore, methods that are able to infer CNVs from gene expression data would
help maximize the value of these studies.
Results: We developed a framework for identifying recurrent regions of CNV and distinguishing the cancer driver
genes from the passenger genes in the regions. By inferring CNV regions across many datasets we were able to
identify 109 recurrent amplified/deleted CNV regions. Many of these regions are enriched for genes involved in
many important processes associated with tumorigenesis and cancer progression. Genes in these recurrent CNV
regions were then examined in the context of gene regulatory networks to prioritize putative cancer driver genes.
The cancer driver genes uncovered by the framework include not only well-known oncogenes but also a number
of novel cancer susceptibility genes validated via siRNA experiments.
Conclusions: To our knowledge, this is the first effort to systematically identify and validate drivers for expression
based CNV regions in breast cancer. The framework where the wavelet analysis of copy number alteration based
on expression coupled with the gene regulatory network analysis, provides a blueprint for leveraging genomic
data to identify key regulatory components and gene targets. This integrative approach can be applied to many
other large-scale gene expression studies and other novel types of cancer data such as next-generation
sequencing based expression (RNA-Seq) as well as CNV data.
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Background
Tumors arise from the activation of oncogenes along
with the inactivation of tumor suppressor genes via
somatic gene mutations or copy number variation
(CNV). Identification of the genetic/genomic changes
that drive biological processes associated with cancer
onset or progression assists in the development of thera-
peutics targeting the affected proteins or their down-
stream consequences[1-4]. Although extensive gene
expression studies have been conducted for identifying
tumor signature genes associated with poor outcome
[5,6], the reproducibility of these signatures is low[7,8],
posing a major challenge for identifying the causal
genetic/genomic variations.
Genome-wide DNA copy number variation (CNV) has
been increasingly used for identifying biomarkers and
targets in cancer research[9-11]. Unfortunately, the
CGH, SNP genotype, and DNA sequencing data typi-
cally used to detect CNV are not available for many
published, large-scale studies. Therefore, the develop-
ment of methods to infer CNV from non-genetic data
collected in these studies would serve to enhance their
scientific value. Strong correlations between CNV and
gene expression have been observed[11,12] and initially
suggested the possibility of detecting CNV directly from
gene expression data. Recently, the Analysis of Copy
number alteration by Expression (ACE) algorithm was
developed to identify amplified or deleted chromosome
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approach demonstrated the utility of leveraging expres-
sion data to identify candidate CNV regions and genes
whose expressions might be affected by the candidate
CNV, the identified regions were often large and har-
bored many genes. Furthermore, no objective mechan-
ism was employed to distinguish cancer driver genes
from passenger genes within a putative CNV region.
Here we describe a novel Wavelet based Analysis of
Copy number alteration by Expression (WACE) algo-
rithm and combine it with Bayesian networks via a key
driver analysis to provide a systematic and unified
approach for distinguishing cancer driver genes from
passenger genes residing in inferred copy number varia-
tion sites.
Methods
Preprocessing data
We collected four independent breast cancer datasets,
NKI[14], Wang[6], Miller[15], and Christos[8]. NKI
samples were profiled on the Agilent Human 25 K plat-
form comprised of 24,496 non-control oligonucletoide
probes while the other studies were carried out using
the Affymetrix HG133A platform, compromised of
22,282 probe sets. Each of the four microarray datasets
was adjusted for estrogen and progesterone receptor
(ER/PR) status as well as age to avoid their influence.
The data were fit using a robust linear regression model
(rlm function from R statistical package), and the resi-
duals with respect to the model fit were carried forward
in all subsequence analyses as the gene expression traits.
In all analyses except ACE, the expression of individual
gene/probe was used. In the subsequent analysis, for a
gene with multiple probes we used the average expres-
sion profile to represent its expression so as to eliminate
the weight effect due to multiple data points on a single
location.
We also downloaded the gene expression and aCGH
data from the Stanford University Breast Cancer Study
http://smd.stanford.edu/[16]. Again the expression pro-
files of multiple probes representing the same gene were
consolidated by average. The expression and aCGH data
were adjusted for array batch, ER/PR status and age to
avoid their influence.
A Unified Framework for Expression based CNV Inference
and Causal Gene Identification
We developed a framework for integrating CNV infer-
ence and gene regulatory network analysis to provide a
systematic and unified approach to prioritizing genes
residing in inferred CNV (ICNV) regions (Figure 1).
Under this framework, we first developed a wavelet-
based ACE algorithm (WACE) to more efficiently and
accurately detect amplified/deleted regions of the
genome in cancer samples. For a given gene expression
study the samples are first classified into two groups
based on phenotypes such as poor versus good outcome
and the two corresponding subsets of gene expression
data are then taken as input for WACE to infer signifi-
cantly amplified or deleted CNV regions. Meanwhile, a
regulatory network is constructed using the Bayesian
network reconstruction method. Finally, genes on the
inferred CNV regions are input into a key driver analysis
to identify hub genes in the network as potential cancer
driver genes. When multiple datasets are available, all
ICNV regions are aligned to form recurrent CNV
regions and multiple regulatory networks are combined
into a single network. The recurrent CNV regions and
the combined network then go through the key driver
analysis to identify putative regulators.
Wavelet based Analysis of Copy number alteration by
Expression (WACE)
WACE algorithm is described in detail in the Method of
Additional File 1 and summarized by a diagram in Fig-
u r e2 .I nb r i e f ,f o rag i v e nd a t a s e t ,t h eg e n ee x p r e s s i o n
traits were first ordered according to their physical loca-
tion on chromosomes. The expression scores (ES, t-sta-
tistics) were computed for each gene with respect to the
good and bad tumor outcome, and were then subjected
to wavelet transform to obtain the neighboring scores
(NS). To evaluate the significance of the NS’s on each
Figure 1 A framework for integrating wavelet based CNV
inference and gene network analysis. The samples in a given
gene expression study are first partitioned into two groups based
on phenotypes such as poor versus good outcome, followed by
differential expression analysis (t-test) to yields expression scores (ES
t-statistics). Wavelet analysis is then performed on ES’ ordered by
gene chromosomal locations to detect significant consecutive
regions (called inferred CNV regions). Using the same gene
expression data, a gene regulatory network (Bayesian network) is
constructed. Finally, the inferred CNV regions and the Bayesian
network are input to the key driver analysis to identify potential
cancer driver genes.
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null distribution by applying wavelet transform to “ran-
dom” ES’s based on randomizing the sample class labels
with respect to the expression vectors, repeating this
process 1000 times. The false discovery rate for each
observed NS was computed as the fraction of random
NS’s that were greater than (less than) or equal to the
observed value if NS > 0 (NS < 0). After evaluating the
statistical significance of NS, an ICNV region on a chro-
mosome was identified if it harbored at least n consecu-
tive positive/negative NS’s at a false discovery rate <
0.01. The n value, which varied from 5 to 10, was pro-
portional to the scaling level used in wavelet transform
w h i c hi nt u r nr e l a t et ot h eg e n e / p r o b ed e n s i t yo ft h e
microarray platform. A high scaling level of wavelet
transform increases the NS magnitude of neighbor
points around a single differentiated gene, and thus
makes them become statistically significant, which
might in turn falsely identify a region as ICNV if n is
small (Additional File 1, Figure S1B). Therefore, n value
is determined by the scaling level used in wavelet trans-
form. The higher scaling level requires large n. We have
tested different n values from 5 to 10 for a given s = 5
in the Stanford data which is comprised of both aCGH
and expression data. We have found that n = 10 pro-
vides the best overlap between aCGH-and expression-
based expression. Similarly, n = 5 which corresponds to
s = 3, provides robust results for identifying recurrent
ICNV regions. Finally, ICNV regions in multiple data-
sets were aligned to determine the recurrent CNV
regions. The selection of filter function and scaling level
for wavelet transform, as well as the validation of the
method, is discussed in detail in Additional File 1.
Distinguishing cancer driver genes from passenger genes
via reconstruction of Bayesian networks
CNV regions harbor many genes but only a small por-
tion of them are cancer causal genes. A key challenge in
cancer genomics is to distinguish the cancer driver
genes, which are causal for oncogenesis and whose var-
iations confer growth advantage on cancer cells, from
the passenger genes that are physically located close to
the driver genes in CNV regions[17]. Several methods
have been proposed to indirectly identify driver genes
by intersecting genes associated with CNV regions and
gene coexpression networks[18] or protein-protein
Figure 2 Outline of the WACE algorithm. For a given gene expression dataset, the samples are classified into two groups based on
phenotypes such as poor versus good outcome and the genes are ordered based on their physical location on chromosomes. Expression scores
(ES, t-statistics) for all the genes are computed and then subjected to wavelet transform to obtain smoothed ES, called neighboring score (NS).
The significance (false discovery rate, FDR) of NS on each individual chromosome is empirically approximated based on its null distribution by
performing the same wavelet transform on “random” ES’s based on the randomized samples. A segment containing at least n consecutive
positive/negative NS with FDR ≤ 0.01 is defined as an inferred CNV region. ICNV regions from multiple datasets are finally aligned to determine
the recurrent regions of CNV.
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two neighbor genes in an inferred CNV region (shown
in Figure 3) are correlated to the inferred CNV (as
implicated by the WACE method). To distinguish the
potential cancer drivers, we tested whether they can
causally regulate other genes instead. As shown in Fig-
u r e3 ,t w oc a n d i d a t eg e n e sC 1 and C2 are cis regulated
by a common CNV. To determine whether a down-
stream gene G is regulated by C1 or/and C2 or neither
is equivalent to select among competing models:
g ∼ ε (1)
g ∼ f(c1) (2)
g ∼ f(c2) (3)
g ∼ f(c1,c2) (4)
where eq. (1) represents G independent of C1 and C2,
eq.s (2) - (4) represent G regulated by C1 ,C 2, both C1
and C2, respectively. As there are many other potential
genes or factors that can affect the expression levels of
gene G, the models eq. (1) - (4) are needed to condition
on all other such factors. Thus, the model selection pro-
cess is equivalent to a Bayesian network reconstruction
process, which will be discussed subsequently.
Bayesian network is a probabilistic representation of
the gene regulatory network and has shown superior per-
formance in integrating genetic data into gene causal
networks predictive of complex phenotypes[20-25].
6,312, 6,349, 6,268 and 5,802 differentially regulated
genes for NKI[14], Wang[6], Miller[15], and Christos[8],
respectively, were selected as input into a Bayesian net-
work reconstruction software program based on a pre-
viously described algorithm[24]. Markov Chain Monte
Carlo (MCMC) simulation was then employed to identify
the most plausible structures. For each seed, 15*n
2 itera-
tions of MCMC were run on average, where n is the
number of nodes. The Bayesian Information Criterion
(BIC) scores were used as the optimization criteria. One
thousand Bayesian networks were reconstructed using
different random seeds to start the reconstruction pro-
cess. From the resulting set of 1000 networks generated
by this process, edges that appeared in greater than 30%
of the networks were used to define a consensus network.
The cutoff of 30% was based on a simulation study[26].
When summarizing 1000 constructed structures from
random seeds, the histogram of the number of link
occurrences among 1000 structures shows a bimodal dis-
tribution, where 30% is the best value to separate the two
modes and also has the best recall-precision tradeoff [26].
E d g e si nt h i sc o n s e n s u sn e t w ork were removed if 1) the
e d g ew a si n v o l v e di nal o o p ,a n d2 )t h ee d g ew a st h e
most weakly supported of all edges making up the loop.
Key Driver Analysis (KDA)
One primary goal of gene network analysis is to identify
k e yr e g u l a t o r yc o m p o n e n t s ,o rk e yd r i v e r s ,o fs u b - n e t -
works with respect to varying biological contexts
[25,27]. The KDA takes as input a set of genes (G)a n d
a gene causal (directed) network N. The objective is to
identify the key regulators for the gene sets with respect
to the given network. Candidate drivers are identified as
follows. We first compute the size of the h-layer neigh-
borhood (HLN) for each node. The range of h is from 1
to the diameter of the network N. Specifically, for a
given node g, the size of its HLN is the number of its
downstream nodes that are within h edges away from g.
For the given network N,l e tμ be an array of the sizes
of HLNs and d be an array of the out-degrees for all the
nodes. The nodes are nominated as candidate drivers if
their sizes of their HLN are greater than μ + σ(μ),
where μ is the mean of μ is and s(μ)i st h es t a n d a r d
deviation of μ. The candidate drivers without any parent
node (i.e., root nodes) are nominated as global drivers
while the rest are local regulators. Let d be the mean of
d and s(d) be the standard deviation of d.W ea l s op r o -
mote hub nodes as global drivers, i.e., the nodes with
out-degrees above d +2 σ(d) are designated as global
drivers. These criteria identify genes with number of
downstream nodes or number of outlinks significantly
above the average.
Figure 3 Cancer driver genes versus passenger genes.T w o
candidate genes C1 and C2 are located on an inferred CNV region,
and are likely cis regulated by a CNV. To distinguish potential
drivers from passengers, we test whether they can causally regulate
other genes. To determine whether a downstream gene G is
regulated by C1 or/and C2 or neither is equivalent to selection
among four competing models. Given that many other potential
genes or factors affect the expression level of gene G, the models
conditioning on all other factors are needed to evaluate, i.e., a
Bayesian network reconstruction process.
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its downstream nodes. Previous work has shown that a
gene’s function can be predicted by its neighbor genes
in networks[28]. Moreover, a series of validation experi-
ments show that the downstream nodes of a driver pre-
dicted by Bayesian networks significantly overlap with
its knockout signature[25].
siRNA Screen and Cell Viability Assays
Cell lines and siRNA library
Four different breast cancer cell lines, ER-positive MCF7
and ZR-75-1; and ER-negative MDA-MB-231and MDA-
MB-468[29], were obtained from the American Type
Culture Collection, Rockville, MD (Catalogue numbers
HTB-22, HTB-26, HTB-132 and CRL-1500, respec-
tively). The siRNA library targets ~2,400 unique human
genes, with three siRNAs per gene, as described pre-
viously[30]. The library represents genes comprising
kinases, membrane proteins, enzymes, components of
major cellular pathways including cell cycle, transcrip-
tion regulation, and signal transduction, etc. [31]. siRNA
sequences were designed with an algorithm developed
to increase efficiency of the siRNAs for silencing while
minimizing their off-target effects [32]. siRNAs were
ordered from Sigma-Proligo (The Woodlands, TX).
siRNA screen and cell viability assays
siRNA screens were performed as described previously
[30] and cells were transfected using RNAiMAX (Invi-
trogen, Carlsbad, CA). Cell viability assay was deter-
mined using AlamarBlue reagent (BioSource
International, Camarillo, CA). The fluorescence signal
was corrected for background (no cells). Cell growth
was expressed as % viability relative to the median value
of wells transfected with an siRNA to Luciferase.
Results
As detailed in the Materials and Methods, the proposed
unified framework for expression based CNV inference
and causal gene identification is comprised of three
major components, wavelet based CNV inference, causal
network construction and key driver identification.
Performance Comparison of WACE and GACE
The original ACE approach for identifying amplified or
deleted chromosome regions used the simple Gaussian
transform to smooth the data and then identified the
significantly abnormal regions comprised of over- or
under-expressed genes via a permutation test[13].
Although this approach, named GACE, was able to nar-
row down genes whose expression might be affected by
the local CNV, it often systematically overestimated the
size of the identified regions which were typically re-
arrangements of small sequences. We improved GACE
by introducing: i) a wavelet based smoothing technique
and ii) a new statistical method for assessing significance
of putative CNV regions. Wavelet transform is a more
sophisticated filtering technique and has become a cut-
ting-edge technology in signal and image processing
because of its superior ability to accurately deconstruct
and reconstruct finite, non-periodic and/or non-station-
ary signals[33]. This led to a wavelet-based ACE algo-
rithm (WACE) to efficiently and accurately narrow
down amplified/deleted regions of the genome in cancer
samples.
To access the performance of WACE, first we com-
pared it with the existing method GACE based on a pre-
viously published breast cancer study [16], which
consisted of gene expression and aCGH data, as well as
clinical data relating to tumor progression (referred to
here as BCS1). A detailed comparison is described in
Additional File 1, WACE and GACE Comparison (Sec-
tion 2.1). Figure S4 to S6 in Additional File 1 illustrated
the comparison results between two methods based on
(i) the correlation coefficient between the expression-
a n da C G H - b a s e dN Sp r o f i l e s ,a n d( i i )r e - i d e n t i f y i n g
CNVs based on gene expression, respectively. Here we
summarize the findings: (i) WACE uncovered almost
three times as many expression ICNV regions overlap-
ping with the aCGH ICNV regions compared to GACE,
and (ii) these two sets of regions identified by WACE
were better correlated with each other than those identi-
fied by GACE.
We also verified the cis-effect of CNV on gene expres-
sion by considering the correlation between the aCGH
and gene expression data of each gene in BCS1. The
expression of the genes located in the overlapped CNV
regions was highly correlated to the corresponding
aCGH data. For instance, WACE identified in both
expression and aCGH data a DNA amplification region
at 20q13, and the gene expression and aCGH NS pro-
files were highly correlated (r = 0.55).
Amplified regions associated with poor outcome affect
cell cycle
We applied WACE to the aforementioned four breast
cancer microarray studies [6,8,14,15] to infer CNV
regions associated with metastasis. Each dataset was
independently analyzed by WACE and the identified
regions were then aligned to locate the recurrent regions
of ICNVs. To calculate the ES’s for each dataset, the
samples were classified into two groups, the patients
with metastases within 5 years and those with no metas-
tasis after more than 5 years of follow-up.
Figure 4 shows the NS profiles on chromosome 8.
WACE identified the amplified chromosome 8q21-q23
region (around 100 Mb and harboring the MTDH gene)
in three of the four datasets. The amplification of this
region has previously been experimentally verified [13].
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bands associated with tumor outcome. The 8q24 cyto-
band, which was consistently detected as an amplified
region by WACE, was found to be the most frequently
amplified region by genome-wide array CGH[9,12],
where the expression of the underlying genes also
reflected the change in DNA copy number[12]. More-
over, this region also includes the well-known oncogene
MYC.
The recurrent regions of CNV were defined as the
union of the regions in which the abnormal gain/loss
events were identified in at least two out of the four stu-
dies. WACE found 109 recurrent regions covering 2,560
genes (Table 1 and Additional File 1, Table S1). Table 1
lists the recurrent regions of amplification that were
consistently found by WACE in all four datasets. Several
regions on chromosome 8, 11, and 20 identified here
have been previously identified via analysis of CGH
arrays applied to breast cancer tumors [10]. These
results further confirm the accuracy of WACE. We note
that many of the genes in the inferred recurrent regions
were oncogenes (19 of total 84 oncogenes according to
Panther database) or significantly affected the cell viabi-
lity based on siRNA experiments (Figure 5).
These regions were tested for gene enrichment using
the gene ontology (GO) categories, KEGG, Panther, and
GeneGo pathways. The most enriched categories include
nucleosome assembly (P < 7.24E-22), chromatin assem-
bly (P < 1.02E-20), systemic lupus erythematosus (P <
9.03E-18), chromatin assembly or disassembly (P <
4.57E-17), DNA packaging (P < 1.29E-16) and protein-
DNA complex assembly (P < 1.92E-11). Cell cycle and
cholesterol biosynthetic process pathways are also
enriched in the regions. All the enriched categories are
shown Additional File 1, Table S3.
ICNV regions versus aCGH based regions
We further examined to what extent the recurrent
CNVs inferred by gene expression reflect the recurrent
CNVs based on an independent aCGH data in BCS1.
To ensure an objective comparison, we used a popular
CNV detection method, the circular binary segmenta-
tion (CBS) algorithm (implemented in the DNAcopy
package from Bioconductor) on the aCGH data. Forty
six or 68.7% of the 67 CBS based aCGH CNV regions in
BCS1 significantly (gene-based FET P = 3.1e-13) over-
lapped with the 109 recurrent ICNV regions detected by
WACE on the four gene expression studies. The over-
lapped regions on chromosome 8, 11, and 20 have been
previously identified via analysis of CGH arrays applied
to breast cancer tumors [10]. These results demonstrate
a good correspondence between the inferred CNV
regions and the experimental results and thus confirm
the accuracy of WACE.
Breast Cancer Gene Regulatory Networks
Four whole-genome gene regulatory networks were first
constructed by the Bayesian network reconstruction
method [26] for the aforementioned four breast cancer
studies (NKI, Christos, Miller, and Wang) and then
were combined by union of directed links to form a sin-
gle network, which consisted of 10,118 genes and 20,732
directed links. Previous works have shown that genes
controlling many other genes in gene regulatory net-
works are more likely regulatory genes regulating their
downstream genes[24,25,27]. The top 5 genes with the
most out links are ARF1, FOXA1, ESR1, HIF1A and
UBE2C. ARF1 is involved in the activation of the PI3K/
AKT pathways which regulate cell survival and prolifera-
tion[34]. HIF1A p l a y sa ne s s e n t i a lr o l ei nc e l l u l a ra n d
systemic homeostatic response to hypoxia was recently
found to regulate the metastasis of breast tumor to lung
[35]. FOXA1, ESR1 and UBE2C, are known as breast
cancer prognosis biomarkers[36]. The global features of
the combined network are described in detail in
Figure 4 NS profiles on chromosome 8 from the four
independent breast cancer studies using WACE. Red lines
encode identified CNV regions. MYC neighborhood region (121-133
Mb) is detected to be amplified in two studies by WACE but only in
one study by GACE.
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Networks (Section 3).
Key Driver Analysis
We assume that the cancer driver genes have broad
impacts on global gene expression while passenger
genes have small impacts [37]. To quantify impacts of
genes residing in the recurrent ICNVs detected across
multiple data sets, we count numbers of downstream
genes that are regulated by each candidate gene locally
or globally in the combined network. Genes are grouped
into global drivers, local drivers and passengers accord-
ing to the rank of these numbers (see Methods for
details). In the key driver analysis, we focus on the
genes residing in amplified regions which are regarded
as a hallmark of dominant cancer driver genes[17].
For the genes in the recurrent regions of amplification
(RR Gain), we identified 44 global drivers and 24 local
drivers. Known breast cancer susceptibility genes like
TPX2, AURKA, TK1 and BIRC5 are among the top 7
global drivers (the other 3 top drivers are GINS2,
COX4NB and NUP93). Other known breast cancer gene
target such as ERBB2, E2F1 and MTDH are in the glo-
bal driver list. Many of them such as aurora kinases
AURKA and survivin (BIRC5) have been targets for
anticancer drugs [38-40].
To access the robustness of predicted key drivers, we
performed the KDA on the networks (named as the
3N networks) as combinations of any three of the four
Bayesian networks. Over 79% of the drivers based on
the 3N networks are the drivers based on the combi-
nation of all the four BNs. On the other hand, the four
driver sets based on the 3N networks significantly
overlap with each other (with FET p-values < 1E-14)
and they share at least 41% of their members. There-
fore, the drivers uncovered are fairly robust. It is of
note that the network based on all the four networks
leads to many more drivers than any 3N network, indi-
cating the great advantage of the combination of all
the networks.
Validation of key drivers via in vitro siRNA knockdown
experiments
We assessed the effect of knocking down the genes
located on the amplified recurrent ICNV regions by
siRNA on breast cancer cell viability because they were
enriched for gene sets involved in cell cycle and meta-
bolic regulation. In the previously described siRNA
experiments, the median of the viability of the siRNA
transfected cells was 64.30%, with a standard deviation
of 15.28%, compared to the control cells transfected
with an siRNA to luciferase. We used a viability cutoff
value of 41.38% (1.5× standard deviation below the med-
ian) to determine viability signature genes that, when
silenced, significantly decrease cell viability. This
resulted in the identification of a 216 gene signature
(V1) with a significant effect on cell viability in multiple
cell lines. Based on a cutoff of 1.5× standard deviation
below the median, we also derived a signature for each
cell line. The four signatures from individual cell lines
were then combined with V1 to derive a combined sig-
nature V2 with 484 genes. The genes in V1 and V2 and
their viability scores are shown in Additional File 2,
Table S4.
Table 1 The inferred recurrent regions of CNV in the four breast cancer datasets.
Cytoband
Location
Chr Start
(Mb)
End
(Mb)
Size
(Mb)
Gain/
Loss
Important genes
chr3q26.31-q27.1 3 173.95 185.91 11.96 G ECT2, PIK3CA, PSMD2, CLCN2, POLR2H
chr4p16.3 4 0.69 1.95 1.26 G CTBP1, TACC3
chr5q35.2-q35.4 5 173.41 179.09 5.69 G GRK6, DDX41
chr8p21.2-p12 8 23.59 30.70 7.11 L CLU
chr8q24.3 8 143.54 146.25 2.71 G NRBP2
chr11q13.1-q13.4 11 64.54 71.59 7.05 G MAP3K11, ADRBK1, RPS6KB2, LRP5, CPT1A
chr12q24.23-
q24.33
12 120.70 122.32 1.62 G
chr16p13.4 16 2.02 2.66 0.64 G DCI, PDPK1
chr16q12.2-q22.1 16 54.25 69.11 14.87 G POLR2C, KIFC3, CSNK2A2, GOT2, CDH5, PSKH1, PSMB10, VPS4A,
chr16q22.3-q24.3 16 82.56 88.62 6.06 G GALNS
chr20q11.1-q11.23 20 28.24 36.99 8.75 G TPX2, APBA2BP, E2F1, EIF2S2, AHCY, GSS, PROCR, RBM39, SCAND1, DLGAP4,
GHRH, BLCAP
chr20q13.12-
q13.13
20 44.43 49.01 4.58 G ARFGEF2, CSE1L
The important genes include known oncogenes, known tumor suppressors, and the genes that, when silenced, reduced cell viability by more than 50% basedo n
our siRNA experiments.
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cantly enriched in different gene sets including the glo-
bal drivers, the local drivers, the drivers (global and
local), the non-driver genes and the genes not on the
recurrent regions (nonRR). Figure 5 shows the fold
enrichment of each gene set for the siRNA hit signa-
tures V1 and V2. When compared with the genes not
on the recurrent ICNV regions, the genes on these
regions are about twice (i.e. 2.1 and 1.8 vs. 0.9) more
likely to fall into V1 and V2, respectively. Also the glo-
bal drivers are most likely to be siRNA hits in both V1
and V2, followed by local drivers and non-drivers. For
example, the global drivers, the local drivers and the
non drivers are 7.8 (P < 5.8e-4), 4.8 (P < 1.9e-2) and
1.97 (P < 2.5e-6) times more likely to overlap with V1,
respectively than the genes on the human genome.
When the genes on the recurrent ICNV regions were
considered as background, the global drivers were 4.2 (P
< 0.0055) and 3.5 (P < 0.003) times more likely to be in
V1 and V2, respectively, and the local drivers are less
significantly enriched for the signatures.
Seven drivers (ATP6V1C1, BIRC5, DDX19A, DDX28,
E2F1, PSMC5 and TPX2) are in V1. The protein Survi-
vin is encoded by BIRC5 (located in 17q25) and is well-
known for its role in mitotic regulation and apoptosis,
and has been developed as a target for cancer treatment
Figure 5 Validation of predicted key drivers by testing the enrichment of siRNA hit signatures in various gene sets.T w os i R N Ah i t
signatures, V1 (an across cell line signature with 216 genes) and V2 (with 484 genes as a union of the signatures across cell lines and from the
individual cell lines), were tested for enrichment in the following gene sets: the genes not on the recurrent regions (nonRR), the genes on the
amplified ICNV regions (RR Gain), the non-driver genes (non Drivers) on the amplified regions, the drivers (global and local), the local drivers and
the global drivers. The drivers and non-drivers were based on the key driver analysis on the amplified regions and the Bayesian network. A) and
B) shows the fold enrichment of V1 and V2 signatures in the gene sets, respectively. The genes on the recurrent ICNV regions are more than
twice more likely to enriched for the siRNA signatures than the genes not on the recurrent regions while the global drivers has the highest
likelihood (7.8 and 5.9), followed by the drivers (6.8 and 5.4), the local drivers (4.8 and 4.4), and the non drivers (2 and 1.7).
Tran et al. BMC Systems Biology 2011, 5:121
http://www.biomedcentral.com/1752-0509/5/121
Page 8 of 12[39]. Silencing BIRC5 decreased the cellular viability by
64%. TPX2 is located on 20q11 and the cell viability
dropped by 64% when it was silenced. Figure 6 shows
the subnetwork associated with the amplified recurrent
ICNV regions. The global and local drivers are high-
lighted in different sizes. The genes found in the signa-
ture V1 are highlighted in green.
As mentioned earlier, AURKA and TPX2 are the top
key regulators of the recurrent ICNV regions. On the
other hand, 107 of the genes on the recurrent regions
overlapped with V2 and they include TACC3, ECT2,
CDC6, NOTCH1,a n dPIK3CA etc. Here we found a
molecular mechanism that linked TACC3 and TPX2
through AURKA. TACC3, located on an amplified
region on 4p16, recently emerged as an important gene
in the stabilization of the mitotic spindle[41], and is up-
regulated in several cancer cell lines including thyroid
and lung cancers[42-44]. Cell viability was reduced by
59.80% in the TACC3 siRNA transfected cells. AURKA
resides on 20q13, which was also identified as a recur-
rent region of amplification. It has previously been
shown that TPX2 is one of several activators for
AURKA [45], which in turn controls the localization of
TACC3 to the spindles [46]. Furthermore, TPX2 acts as
an allosteric activator of Aurora A, and together they
inhibit the activity of tumor suppressor p53 in Xenopus
Oocytes (Pascreau et al. 2009). The molecular interaction
between the hubs located on different recurrent regions
might suggest the trans-association between regions. We
expect more mechanisms of this kind will be unraveled
through the integration of WACE and network analysis.
These experimental results demonstrate the impor-
tance of the recurrent ICNV regions and the predicted
key driver genes, especially global drivers in terms of
significant impact on cancer cell viability, and thus vali-
date our procedures for inferring CNV regions and
identifying cancer driver genes in these inferred CNV
regions.
Discussion
We developed a novel Wavelet based algorithm to Ana-
lyze Copy number alteration based on Expression
(WACE) and further combined this analysis with gene
regulatory network analysis to identify the cancer driver
genes in the chromosome regions with genomic altera-
tions. The performance of these two methods was evalu-
ated in Additional File 1, Section 2. In brief, WACE
improved on the state-of-the-art algorithm (GACE) by
Figure 6 A regulatory network for the genes on the amplified recurrent ICNV regions. The key driver analysis was applied to the genes
on the regions and the combined Bayesian network to identify potential key drivers. The largest nodes in the network are the global drivers
and the medium size nodes are local drivers while the non-drivers are the smallest nodes. The genes found in the siRNA signature V1 are
highlighted in green.
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transform and retaining the local patterns, and (ii) elimi-
nating the type I and II errors induced by the non-zero
centered null distribution (Additional File 1, Figure S2).
WACE demonstrated superior performance over GACE
on several large scale gene expression datasets (see
Additional File 1, Section 2). By analyzing multiple data-
sets, we were able to identify recurrent ICNVs that har-
bor many cancer-related genes, suggesting genes in
these regions are worthy of further study.
Integration of the recurrent regions identified by
WACE and the gene regulatory network analysis uncov-
ered not only many well-known oncogenes like BIR-
C5and E2F1, but also a number of novel cancer
susceptibility genes such as ECT2, TPX2 and TACC3,
which are involved in cell cycle and ECM regulation.
Many of the cancer driver genes we predicted were sub-
sequently validated via siRNA experiments. Table S5 in
Additional File 1 includes the four known and 45 novel
breast cancer genes that are in the recurrent regions of
amplification and validated by the siRNA experiments
across multiple breast cancer cell lines.
The importance of the identified recurrent regions of
amplification (ARR) and the inferred drivers are further
justified by another independent dataset from Cancer
Gene Census http://www.sanger.ac.uk/genetics/CGP/
Census/. Among the 19 known breast cancer genes
compiled by Cancer Gene Census, 5 are located in the
ARRs while 14 are outside the ARRs, indicating that the
known breast cancer driver genes are 3.5-fold overrepre-
sented in the ARRs when compared to the genes not on
these regions. Among the 5 census genes located in the
ARRs, one (ERBB2) is the global key driver and the rest
f o u ra r en o tt h ed r i v e r s ,r e p r e s e n t i n g2 5 -a n d2 - f o l d
enrichments, respectively, compared to randomly
selected human genes.
There are multiple molecular factors contributing to
poor outcome, including cell proliferation, metastasis
and cell stemness etc. Our assumption is that CNV sig-
nificantly contributes to the disease outcome though the
separation of the samples into good and bad outcome
groups tends to identify metastasis genes. We don’t
need to pre-specify through what molecular mechanism
that CNV drives disease outcome, which can be inferred
in a data-driven manner. To further understand the
functions of the ARRs, we performed gene co-expres-
sion network analysis[47,48] on the four breast cancer
datasets to identify gene modules (comprised of highly
interacted genes). A module enriched for cell cycle
genes (named as cell cycle module) and conserved
across the four corresponding networks is most predic-
tive of survival in all the four studies, indicating cell
proliferation contributes to breast cancer outcome. The
ARRs are highly enriched for the genes of the cell cycle
module (P < 1.2e-14). This is further supported by the
fact that the inferred key drivers include not only
known breast cancer metastasis genes (MTDH[13] and
ERBB2[49]) but also known cancer cell cycle genes such
as TPX2, AURKA, E2F1 and BIRC5. As shown in Figure
6, these known cell cycle and metastasis genes interact
with each other and with many other drivers to co-regu-
late the genes on the AARs. Furthermore, AARs are
enriched (2.3 fold-enrichment, P < 2.6e-2) for a cell
cycle prognostic signature identified as metastasis mar-
kers[50], and two (AURKA and BIRC5) of the thirty-
three signature genes are the global key drivers (32 fold-
enrichment, P < 1.8e-3). Therefore, cell viability assay,
used to test cell proliferation, at least partially validated
our drivers. The future experiments will consider cell
mobility assay to test how these inferred key drivers
impact cancer cell mobility that drives metastasis.
A recent paper by Akavia et al. describes a method to
predict cancer driver genes by integrating CNA and
gene expression data[51]. Akavia et al’s approach bears
certain similarity as ours. Both approaches first define
gene groups of interest, then identify genes in the
groups with cis-CNV as candidate driver genes. As we
discussed in the main text, expression levels of genes in
t h es a m eC N Vs e g m e n t sa r el i k e l yt ob ec o r r e l a t e ds o
that they are assigned into the group. Candidate genes
(with cis-CNV) in the same co-expression module are
equivalent so that we cannot rank which candidate
genes are more likely to be drivers. Akavia et al. used a
literature based method to rank candidate genes. Basi-
cally, they chose genes with known connections to can-
cers. However, our approach is completely data driven.
We first constructed causal networks to dissect how
genes in the regions of interest are regulated and related
to each other and then we ranked candidate genes
based on the causal networks, which is the key driver
analysis described in the main text. As we mentioned in
the previous discussion, majority of the drivers identified
by our approach are novel and thus they won’tb e
picked up by Akavia et al’s literature based approach.
Jornsten et al. recently developed the EPoC method to
integrate CNA and gene expression variations[52]. EPoC
focuses on CNA driving gene expression changes but
disregards the indirect changes through more hubs.
Only genes with CNA can be cancer driver genes based
on the EPoC model. However, our Bayesian network
approach focuses on how genes are causally related to
each other. In our case, predicted cancer driver genes
may or may not have copy number alterations. Theore-
tically, the EPoC method can also derive gene-gene rela-
tionship as Jorsten et al. indicated that gene-gene
relationship matrix A is the inversion of the CNA-gene
relationship matrix G (G = A
-1). However, they showed
that there was no prediction power using the A matrix.
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matrix, they explicitly assumed CNAs are hubs so that
G
-1 is not exactly A. We have showed that gene-gene
networks based on our Bayesian network approach have
prediction power[24-27]. Thus, our method can be com-
plimentary to the EPoC method.
The impact of CNV on gene expression has been
extensively studied[53,54]. In our analysis, we focused
on genes with cis-regulated CNVs. CNVs may result
partial deletions of genes and the functional changes of
the affected genes in turn cause expression changes of
downstream genes. Gene regulatory networks may be
able to capture the effect of these cis-regulated CNVs
on the trans-regulated ones. In our model, we explicitly
assume CNVs cause gene expression changes. There are
many mechanisms that CNV can be arisen[55]. It is pos-
sible that expression changes of genes in DNA repair
processes affect CNV. More sophisticated causal models,
such as dynamic Bayesian network, are needed to cap-
ture these causal relationships. It is of note that there is
a limitation of this transcriptome-based approach. We
may miss kinases or enzymes that drive cancer progres-
sion and metastasis if these kinases’ or enzymes’ activity
changes are mainly due to protein level changes. Com-
plementary proteomic approaches are needed to com-
plement this approach.
Conclusion
The framework where the wavelet analysis of copy num-
ber alteration based on expression coupled with the
gene regulatory network analysis, provides a blueprint
for leveraging genomic data to identify key regulatory
components and gene targets. To our knowledge, this is
the first effort to systematically identify and validate dri-
vers for expression based CNV regions in breast cancer.
This integrative approach can be applied to many other
large-scale gene expression studies and other novel
types of cancer data such as next-generation sequencing
based expression (RNA-Seq) as well as CNV data.
Additional material
Additional file 1: Supplementary Information. Supplementary
methods and results.
Additional file 2: Supplementary Table S4. siRNA screen signatures
and the associated viability scores.
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